Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Screener
News
About

HRMY - Harmony Biosciences Holdings, Inc.... | Finranks

Home

/

HRMY

H

Harmony Biosciences Holdings, Inc. (HRMY)

NGM – Real Time Price. Currency in USD

30.15

-0.03 (-0.10%)

At close: May 12, 2026, 4:00 PM EDT

30.08

-0.07 (-0.23%)

Pre-market: May 13, 2026, 6:08 AM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates

Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.78 per share a year ago.

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also.

Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice

Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice

Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

HRMY or ARGX: Which Is the Better Value Stock Right Now?

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet

Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet

The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 34.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommende.

Videos

No Data

There is no data to display

Press releases

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also.

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and pri.

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight acro.

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical compan.